Safety and Long-Term Success of Persistent Atrial Fibrillation Ablation Using THERMOCOOL SMARTTOUCH® Catheter : Real-World Experience
BACKGROUND: To investigate the real-world clinical experience of persistent atrial fibrillation (persAF) ablation using the THERMOCOOL SMARTTOUCH® catheter with contact force (CF)-sensing ability in a prospective, multicenter registry.
METHODS: Patients with persAF (excluding long-standing persAF) undergoing ablation were enrolled. Primary adverse events (AEs), 12-month success, quality of life (QoL), and correlation of success with CF were assessed.
RESULTS: Overall, 150 patients with persAF (age 61.6 ± 9.4 years; 76.0% male; 90.7% Caucasian; left ventricular ejection fraction 56.9% ± 10.3%; left atrial diameter 41.5 ± 7.9 mm) underwent catheter insertion (safety cohort); 142 met eligibility criteria and were ablated (evaluable cohort). Confirmation of entrance block for all targeted pulmonary veins was achieved in 99.3% of patients. The primary AE rate was 4.0% (6/150), and 12-month success was 63.1% (95% confidence interval: 54.2%-71.4%). A non-significant trend towards higher success was observed in patients with isoproterenol/adenosine challenge vs. those without (73.1% vs. 60.2%, respectively; P=0.065). Investigators stayed within their pre-selected CF working range (catheter-tissue contact stability) 79.7% ± 12.7% of the time. When investigators stayed within the CF range ≥80% vs. <80% of the time, ablation success was 69.2% vs. 58.5%, respectively (P=0.285). QoL improved significantly at 6 months and was sustained through the 12-month follow-up (P<0.0001).
CONCLUSIONS: Symptom control in a real-world setting of persAF ablation using the THERMOCOOL SMARTTOUCH® catheter was 63.1%, with significant improvements in QoL, and trended non-significantly towards increased success in patients receiving isoproterenol/adenosine challenge and when investigators stayed within their pre-selected CF range ≥80% of the time.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Journal of atrial fibrillation - 12(2019), 2 vom: 30. Aug., Seite 2126 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Potter, Tom De [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 12.04.2022 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.4022/jafib.2126 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM305978640 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM305978640 | ||
| 003 | DE-627 | ||
| 005 | 20231225122340.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4022/jafib.2126 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1019.xml |
| 035 | |a (DE-627)NLM305978640 | ||
| 035 | |a (NLM)32002110 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Potter, Tom De |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Safety and Long-Term Success of Persistent Atrial Fibrillation Ablation Using THERMOCOOL SMARTTOUCH® Catheter |b Real-World Experience |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 12.04.2022 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a BACKGROUND: To investigate the real-world clinical experience of persistent atrial fibrillation (persAF) ablation using the THERMOCOOL SMARTTOUCH® catheter with contact force (CF)-sensing ability in a prospective, multicenter registry | ||
| 520 | |a METHODS: Patients with persAF (excluding long-standing persAF) undergoing ablation were enrolled. Primary adverse events (AEs), 12-month success, quality of life (QoL), and correlation of success with CF were assessed | ||
| 520 | |a RESULTS: Overall, 150 patients with persAF (age 61.6 ± 9.4 years; 76.0% male; 90.7% Caucasian; left ventricular ejection fraction 56.9% ± 10.3%; left atrial diameter 41.5 ± 7.9 mm) underwent catheter insertion (safety cohort); 142 met eligibility criteria and were ablated (evaluable cohort). Confirmation of entrance block for all targeted pulmonary veins was achieved in 99.3% of patients. The primary AE rate was 4.0% (6/150), and 12-month success was 63.1% (95% confidence interval: 54.2%-71.4%). A non-significant trend towards higher success was observed in patients with isoproterenol/adenosine challenge vs. those without (73.1% vs. 60.2%, respectively; P=0.065). Investigators stayed within their pre-selected CF working range (catheter-tissue contact stability) 79.7% ± 12.7% of the time. When investigators stayed within the CF range ≥80% vs. <80% of the time, ablation success was 69.2% vs. 58.5%, respectively (P=0.285). QoL improved significantly at 6 months and was sustained through the 12-month follow-up (P<0.0001) | ||
| 520 | |a CONCLUSIONS: Symptom control in a real-world setting of persAF ablation using the THERMOCOOL SMARTTOUCH® catheter was 63.1%, with significant improvements in QoL, and trended non-significantly towards increased success in patients receiving isoproterenol/adenosine challenge and when investigators stayed within their pre-selected CF range ≥80% of the time | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Ablation | |
| 650 | 4 | |a Atrial Fibrillation | |
| 650 | 4 | |a Electrophysiology | |
| 700 | 1 | |a Herendael, Hugo Van |e verfasserin |4 aut | |
| 700 | 1 | |a Balasubramaniam, Richard |e verfasserin |4 aut | |
| 700 | 1 | |a Wright, Matthew |e verfasserin |4 aut | |
| 700 | 1 | |a Laţcu, Decebal-Gabriel |e verfasserin |4 aut | |
| 700 | 1 | |a Agarwal, Sharad C |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Baohui |e verfasserin |4 aut | |
| 700 | 1 | |a Boo, Lee Ming |e verfasserin |4 aut | |
| 700 | 1 | |a Pani, Antonio |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of atrial fibrillation |d 2008 |g 12(2019), 2 vom: 30. Aug., Seite 2126 |w (DE-627)NLM203440056 |x 1941-6911 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2019 |g number:2 |g day:30 |g month:08 |g pages:2126 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.4022/jafib.2126 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2019 |e 2 |b 30 |c 08 |h 2126 | ||